4 Key Pillars for Oncology Launch Success

 Courtney Patterson, PharmD, MBA | Vice President, Clinical Oncology Solutions and Access Experience Team

Over the years, I’ve had a front‑row seat to oncology launches that soared… and others that struggled to find their footing. What’s always struck me is this: The science can be extraordinary, the data airtight, the clinical promise undeniable, yet the launch can still miss the mark.

It’s almost never because the medicine isn’t good enough. More often, it’s because we overlook the human, operational, and real-world factors that determine whether a therapy reaches the patient it was designed for.

When I think about the launches that truly worked, they had four things in common.

1. The Power of a Punchy Message  

I once worked with a team preparing to launch an oncology asset with remarkable potential. But when I asked ten team members who the ideal patient was, I received ten different answers. That’s a clarity problem.

Your internal message must be sharp and consistent. Build a clear, succinct narrative that defines the target patient and articulates why this therapy matters for them.

Research suggests that oncology launches from larger companies often underperform compared to those from smaller organizations. Conway’s Law helps explain why: a product’s design and clarity tend to mirror the organization’s communication structure. Conway’s law states “organization’s which design systems...are constrained to produce designs which are copies of the communication structures of these organizations.”

In larger companies, siloed teams can dilute focus and slow decision-making. A one-size-fits-all launch model also limits the ability to respond quickly to real-time market needs.

Whether you are in a large or small organization, be entrepreneurial and creative. Get intentional and clear about who the patient is, and architect a story that tells how the medication will get from the brain of the scientist to the vein of the patient.

2. Understand the Current Climate 

Some of the most valuable insights I’ve gained came from conversations. Sitting in a cancer center with a pharmacist who walks me through the burden of utilization management. Listening to a nurse explain why an adverse event scares patients more than we assume. Hearing from a practice manager who worries about staffing shortages long before they worry about another therapy on the market.

Invest in understanding the full market landscape. Know the current standard of care, follow emerging research and active trials, monitor shifting policy dynamics, and stay close to the operational realities that shape decision-making in the field. A study that looked at drug launches from 2012 to 2017 found that having a deep understanding of patient needs, value drivers of clinicians, and key stakeholders positioned teams to improve their overall launch performance.

Be intentional about learning how organizations evaluate and integrate new therapies. Qualitative research — including interviews, panels, and workflow reviews — reveals the psychology, value drivers, and processes behind adoption. A review of information found that “Crossing the data from the qualitative interviews and the clinical trial could generate new information on patients’ experience.”

These insights help you anticipate operational barriers, from financial pressures to utilization management tools and payer policies.

3.  Health Equity is a Barrier or a Bridge 

Here’s something I remind teams at every launch: If the patient can’t afford the therapy, the therapy doesn’t work. If the practice can’t manage the operational or financial load, they won’t adopt it, no matter how promising the data is.

Restricted access, high patient cost-sharing, formulary limitations, and inadequate guidance on adverse event management all create hesitancy and can quickly undermine a promising launch.

Consider the financial impact on the organization, thinking of the full spectrum of large academic medical centers to small provider practices. A study found that 47% of U.S. adults report it is very or somewhat difficult to afford healthcare costs. Having a well-built medication assistance program, coupon cards, charity care program, and other discounts for practices (i.e., group purchasing contract discounts) can ease the patient and organizational financial burdens.

Beyond financial resources, provide strong support for clinical management. Clear guidance for adverse event management or REMS requirements reduces provider hesitation and empowers patients and caregivers with the knowledge they need to navigate treatment confidently.

4. Surround-Sound Success Planning

The best teams I’ve worked with anticipate failure. They run premortems, pressure-test assumptions, and ask, “If this launch were to fall apart, why?”

Create an end-to-end strategic plan that includes exercises to identify known and unknown challenges and how the organization will navigate them. Conduct gap analysis, SWOT analysis, and a premortem.

A premortem forces the team to imagine failure from the outset. It surfaces clinical, business, market, communication, and financial risks early, giving you the chance to address them before launch, not after.

The strongest launch teams incorporate every perspective. Providers, payers, nurses, caregivers, social workers, and access specialists each shape adoption. Bringing these voices together creates a surround‑sound view of how the therapy will move through real-world systems.

Why This Matters 

Oncology launch excellence is rarely the result of a single brilliant strategy. It is the discipline of cross-functional alignment, deep market insight, and patient-centered execution. When organizations commit to these four pillars, they create conditions not just for commercial success, but for meaningful impact in patients’ lives.

At the end of the day, that is the true measure of a successful oncology launch.